title: Comparison between high and low molecular weight hyaluronates in knee osteoarthritis patients: open-label, randomized, multicentre clinical trial.
abstract: Efficacy and safety of high and low molecular weight hyaluronates in knee osteoarthritis patients were compared in a randomized, open-label trial. Patients in the high molecular weight hyaluronate group were treated once weekly for 3 weeks and in the low molecular weight group once weekly for 5 weeks. We evaluated weight-bearing pain, degree of flexion, swelling and knee tenderness; frequency and amount of rescue medication; patient and investigator global assessment of pain, and safety over 12 weeks after final injection of study medication. Significant improvements in pain and WOMAC-Likert scores were observed in both groups, but not between groups. Knee joint pain improvement was noted in both groups by patients and investigators during follow-up. Close correlation was observed between patient- and investigator-reported data. There was no significant difference in side-effects between the groups. In conclusion, the efficacy and safety of high and low molecular weight hyaluronate are similar.
authors.affiliation: Department of Anaesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: P B
authors.initials: PB
authors.lastname: Lee
authors.forename: Y C
authors.initials: YC
authors.lastname: Kim
authors.forename: Y J
authors.initials: YJ
authors.lastname: Lim
authors.forename: C J
authors.initials: CJ
authors.lastname: Lee
authors.forename: W S
authors.initials: WS
authors.lastname: Sim
authors.forename: C W
authors.initials: CW
authors.lastname: Ha
authors.forename: S I
authors.initials: SI
authors.lastname: Bin
authors.forename: K B
authors.initials: KB
authors.lastname: Lim
authors.forename: S S
authors.initials: SS
authors.lastname: Choi
authors.forename: S C
authors.initials: SC
authors.lastname: Lee
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects; D000368:Aged; D016009:Chi-Square Distribution; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D007270:Injections, Intra-Articular; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D020370:Osteoarthritis, Knee / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D010146:Pain / Q000188:drug therapy / Q000503:physiopathology; D010147:Pain Measurement; D004364:Pharmaceutical Preparations; D011859:Radiography; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D004364:Pharmaceutical Preparations; D006820:Hyaluronic Acid